natgillin/translations-raw huggingface dataset:
Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/Κύπρος/ Latvija/Lietuva/Luxembourg/Luxemburg/Magyarország/ 
Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/Κύπρος/
- Trombocyttal skal være ≥ 100 x 109 celler/l, og absolut neutrofiltal (ANC) skal være ≥ 1,5 x 109 celler/l. 
- Platelet counts should be ≥ 100,000 cells/μl and the absolute neutrophils count (ANC) should be ≥ 1,500 cells/μl
Gastrointestinal og intracerebral blødning er blevet rapporteret i forbindelse med bortezomibbehandling. 
Gastrointestinal and intracerebral haemorrhage, have been reported in association with bortezomib treatment.
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter) - leverbetændelse - alvorlig allergisk reaktion (anafylaktisk reaktion). 
Uncommon side effects (may affect up to 1 in 100 people) - hepatitis - severe allergic reaction (anaphylactic reaction) signs of which may include difficulty breathing,
Almindelig Hyperbilirubinæmi*, abnorme proteinanalyser*, vægttab, vægtstigning 
Common Hyperbilirubinaemia*, Protein analyses abnormal*, Weight decreased, Weight increased
Responsrate efter 8 cyklusser n (%) ORR (CR+PR) p-værdia 
Response Rate at 8 cycles n (%) ORR (CR+PR) p-valuea
Det er nødvendigt, at du får taget regelmæssige blodprøver før og under din behandling med Bortezomib SUN for at få kontrolleret niveauet af dine blodlegemer. 
You will have to take regular blood tests before and during your treatment with Bortezomib SUN, to check your blood cell counts regularly.
Der foreligger ingen studier af anvendelsen af bortezomib til ældre patienter med tidligere ubehandlet myelomatose, som er egnede til højdosiskemoterapi med hæmatopoietisk stamcelletransplantation. 
There are no studies on the use of bortezomib in elderly patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
12,8 mdr. 
12.8 mo
Til bekræftelse af PRES-diagnosen anvendes hjernescanning, fortrinsvis magnetisk resonans (MR). 
Brain imaging, preferably Magnetic Resonance Imaging (MRI), is used to confirm the diagnosis.
Bortezomib SUN-behandlingen skal tilbageholdes, indtil symptomerne på toksiciteten er vurderet til grad 1 eller baseline. 
Bortezomib SUN therapy should be withheld until symptoms of the toxicity have resolved to Grade 1 or baseline.
Følgende lægemidler gives som intravenøse infusioner på dag 1 i hver 21-ugers behandlingscyklus med Bortezomib SUN: 
The following medicinal products are given on day 1 of each Bortezomib SUN 21-day treatment cycle as intravenous infusions:
Intravenøs anvendelse: Tilsæt 3,5 ml 0,9 % natriumchlorid-injektionsvæske, så den endelige koncentration bliver 1 mg/ml. 
Intravenous use: Add 3.5 ml 0.9% sodium chloride to make 1 mg/ml final concentration.
Dosisjustering er ikke nødvendig hos patienter med let nedsat leverfunktion; patienterne skal behandles med den anbefalede dosis. 
Patients with mild hepatic impairment do not require a dose adjustment and should be treated per the recommended dose.
Neuropati*, perifer sensorisk neuropati, dysæstesi*, neuralgi* 
Neuropathies*, Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia*
I studie MMY-3010 blev induktionsbehandling med bortezomib i kombination med thalidomid og dexamethason [BzmbTDx, n=130] sammenlignet med thalidomid-dexamethason [TDx, n=127]. 
In study MMY-3010 induction treatment with bortezomib combined with thalidomide and dexamethasone [BzmbTDx, n=130] was compared to thalidomide-dexamethasone [TDx, n=127].
Ved sammenligning med patienter med normal leverfunktion ændrede en let nedsættelse af leverfunktionen ikke bortezomibs AUC justeret i forhold til standarddosis. 
When compared to patients with normal hepatic function, mild hepatic impairment did not alter dosenormalised bortezomib AUC.
Samlet overlevelse* Hændelser (dødsfald) n (%) Mediana (95 % CI) 
Overall survival* Events (deaths) n (%) Mediana (95% CI)
43,1 mdr. 
43.1 mo
Du kan få op til 8 behandlingscyklusser (24 ugers behandling). 
You might receive up to 8 cycles (24 weeks).
Dosisjustering af kombinationsbehandling for patienter med progressiv myelomatose Dosisjustering af Bortezomib SUN ved kombinationsbehandling skal følge retningslinjerne, der er beskrevet under monoterapi ovenfor. 
Dose adjustments for combination therapy for patients with progressive multiple myeloma For Bortezomib SUN dosage adjustments for combination therapy follow dose modification guidelines described under monotherapy above.
Hos patienter med MCL (studie LYM-3002) var der en højere forekomst (56,7 % versus 5,8 %) af grad ≥ 3-trombocytopeni i bortezomib-armen (BzmbR-CAP) sammenlignet med non-bortezomibarmen (rituximab, cyclophosphamid, doxorubicin, vincristin og prednison [R-CHOP]). 
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the bortezomib treatment group (BzmbR-CAP) as compared to the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
Bortezomib SUN bruges til behandling af: - myelomatose (kræft i knoglemarven) hos patienter over 18 år: alene eller sammen med lægemidlerne pegyleret liposomal doxorubicin eller dexamethason til patienter, hvis sygdom forværres (er progressiv) efter mindst én forudgående behandling, og som ikke har haft gavn af eller mulighed for at få en transplantation af blodstamceller (knoglemarvstransplantation). 
Bortezomib SUN is used for the treatment of: - multiple myeloma (a cancer of the bone marrow) in patients older than 18 years: alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
Hyperbilirubinæmi*, abnorme proteinanalyser*, vægtstigning, abnorm blodprøve*, forhøjet C-reaktivt protein 
Common Weight decreased Uncommon Hyperbilirubinaemia*, Protein analyses abnormal*, Weight increased, Blood test abnormal*, C-reactive protein increased
BzmbR-CAP=bortezomib, rituximab, cyclophosphamid, doxorubicin og prednison; R-CHOP=rituximab, cyclophosphamid, doxorubicin, vincristin og prednison; PN=perifer neuropati Perifer neuropati inkluderede de foretrukne termer: perifer sensorisk neuropati, perifer neuropati, perifer motorisk neuropati og perifer sensomotorisk neuropati 
BzmbR-CAP=bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy
REKONSTITUTION TIL SUBKUTAN INJEKTION 
RECONSTITUTION FOR SUBCUTANEOUS INJECTION
Bortezomib SUN rekonstitueret opløsning indgives som en intravenøs bolusinjektion af 3-5 sekunders varighed gennem et perifert eller centralt intravenøst kateter efterfulgt af skylning med natriumchlorid 9 mg/ml (0,9 %) injektionsvæske. 
Bortezomib SUN reconstituted solution is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml
Ikke-hæmatologiske, toksiske hændelser af grad ≥ 3 
Grade ≥ 3 non-haematological toxicities
Du må ikke køre bil, motorcykel eller cykle eller arbejde med værktøj eller maskiner, hvis du oplever disse bivirkninger. 
Do not drive or operate tools or machines if you experience such side effects; even if you do not, you should still be cautious.
Dosisjusteringer i behandlingsforløbet og ved genoptagelse af behandling ved monoterapi Bortezomib SUN skal seponeres ved forekomst af ikke-hæmatologisk grad 3-toksicitet eller hæmatologisk grad 4-toksicitet med undtagelse af neuropati som beskrevet nedenfor (se pkt. 
Dose adjustments during treatment and re-initiation of treatment for monotherapy Bortezomib SUN treatment must be withheld at the onset of any Grade 3 non-haematological or any Grade 4 haematological toxicities, excluding neuropathy as discussed below (see also section 4.4).
VDDx=vincristin, doxorubicin, dexamethason; BzmbDx=bortezomib, dexamethason; TDx=thalidomid, dexamethason; BzmbTDx=bortezomib, thalidomid, dexamethason; PN=perifer neuropati Bemærk: Perifer neuropati inkluderede de foretrukne termer: perifer neuropati, perifer motorisk neuropati, perifer sensorisk neuropati og polyneuropati. 
VDDx=vincristine, doxorubicin, dexamethasone; BzmbDx=bortezomib, dexamethasone; TDx=thalidomide, dexamethasone; BzmbTDx=bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy Note: Peripheral neuropathy included the preferred terms: neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.
Demografiske og baseline-sygdomskarakteristika var generelt afbalanceret mellem de to behandlingsarme: Den mediane patientalder var 66 år, 74 % var mænd, 66 % var kaukasere og 32 % asiater, 69 % af patienterne havde et positivt knoglemarvsaspirat og/eller en positiv knoglemarvsbiopsi for MCL, 54 % af patienterne havde en IPI-score (International Prognostic Index) på ≥ 3, og 76 % var i sygdomsstadie IV. Behandlingens varighed (median=17 uger) og varigheden af opfølgningen (median=40 måneder) var sammenlignelige i de to behandlingsarme. 
The demographic and baseline disease characteristics were generally well balanced between the two treatment arms: median patient age was 66 years, 74% were male, 66% were Caucasian and 32% Asian, 69% of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for
Patienterne havde IgG/IgA/lette kæder af myelomer i henholdsvis 63 %/25 %/8 % tilfælde, mediant hæmoglobin på 105 g/l og mediant trombocyttal på 
Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/l, and a median platelet count of 221.5 x 109/l.
- mantle-celle-lymfom (en type kræft, som påvirker lymfeknuderne) i kombination med lægemidlerne rituximab, cyclophosphamid, doxorubicin og prednison til patienter på 18 år og derover, hvis sygdom ikke tidligere er blevet behandlet, og som ikke er egnede til at gennemgå en transplantation af blodstamceller. 
- mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable.
Den samlede forekomst af hepatitis B-infektion var sammenlignelig hos patienter i BzmbR-CAP-armen og patienter i R-CHOP-armen (henholdsvis 0,8 % og 1,2 %). 
The overall incidence of hepatitis B infections was similar in patients treated with BzmbR-CAP or with R-CHOP (0.8% vs 1.2% respectively).
Det er yderst vigtigt, at der anvendes aseptisk teknik under håndteringen af Bortezomib SUN, da det ikke indeholder konserveringsmiddel. 
Aseptic technique must be strictly observed throughout the handling of Bortezomib SUN, since it contains no preservative.
Mindst 6 måneder efter den tidligere behandling initieredes bortezomib med den senest tålte dosis på 1,3 mg/m2 (n=93) eller ≤ 1,0 mg/m2 (n=37); bortezomib blev administreret på dag 1, 4, 8 og 11 hver 3. uge i maksimalt 8 cyklusser enten som monoterapi eller i kombination med dexamethason i henhold til gældende standardbehandling. 
At least 6 months after prior therapy, bortezomib was started at the last tolerated dose of 1.3 mg/m2 (n=93) or ≤ 1.0 mg/m2 (n=37) and given on days 1, 4, 8 and 11 every 3 weeks for maximum of 8 cycles either as single agent or in combination with dexamethasone in accordance with the standard of care.
Du kan opleve et fald i antallet af: - blodplader, hvilket kan gøre dig mere tilbøjelig til at få blå mærker eller til at bløde uden påviselig skade (f.eks. blødning fra tarmene, maven, munden og gummerne, blødning i hjernen eller blødning fra leveren) - røde blodlegemer, hvilket kan forårsage blodmangel med symptomer som træthed og bleghed - hvide blodlegemer, hvilket kan gøre dig mere tilbøjelig til at få infektioner eller influenzalignende symptomer. 
You may experience a reduction in the number of: - platelets, which may make you be more prone to bruising, or to bleeding without obvious injury (e.g., bleeding from your bowels, stomach, mouth and gum or bleeding in the brain or bleeding from the liver) - red blood cells, which can cause anaemia, with symptoms such as tiredness and paleness - white blood cells may make you more prone to infections or flu-like symptoms.
- Trombocyttal skal være ≥ 75 x 109 celler/l hos patienter med infiltreret knoglemarv eller sekvestration af milten. 
- Platelet counts should be ≥ 75,000 cells/μl in patients with bone marrow infiltration or splenic sequestration
Det skal du vide, før du begynder at bruge Bortezomib SUN Brug ikke Bortezomib SUN: - hvis du er allergisk over for bortezomib, bor eller et af øvrige indholdsstoffer i Bortezomib SUN (angivet i punkt 6) 
What you need to know before you are given Bortezomib SUN You should NOT be given Bortezomib SUN - if you are allergic to bortezomib, boron or to any of the other ingredients of this medicine
For disse dosiskohorter var den kombinerede overlevelse efter 1 år 
For these dose cohorts, the combined 1-year survival rate was 88.1%.
I studie LYM-3002 fik 78 % af patienterne i BzmbR-CAP-armen og 61 % af patienterne i R-CHOParmen support med kolonistimulerende faktor. 
In study LYM-3002, colony stimulating factor support was given to 78% of patients in the BzmbR-CAP arm and 61% of patients in the R-CHOP arm.
Det er uvist, om bortezomibs farmakokinetik bliver påvirket hos patienter med svært nedsat nyrefunktion (CrCl < 20 ml/min/1,73 m2), som ikke er i dialyse. 
It is unknown if the pharmacokinetics of bortezomib are influenced in patients with severe renal impairment not undergoing dialysis (CrCL < 20 ml/min/1.73 m2).
Klinisk virkning ved tidligere ubehandlet mantle-celle-lymfom (MCL) Studie LYM-3002 var et åbent, randomiseret fase III-studie, som sammenlignede effekt og sikkerhed af kombinationen af bortezomib, rituximab, cyclophosphamid, doxorubicin og prednison (BzmbRCAP; n=243) i forhold til rituximab, cyclophosphamid, doxorubicin, vincristin og prednison (RCHOP; n=244) hos voksne patienter med tidligere ubehandlet MCL (stadie II, III eller IV). 
Clinical efficacy in previously untreated mantle cell lymphoma (MCL) Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (BzmbR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV).
QT-forlængelse)*, abnorm INR (international normalised ratio)*, nedsat gastrisk pH, øget trombocytaggregation, forhøjet troponin I, identifikation og serologisk test af virus*, abnorm urinprøve* 
Blood gases abnormal*, Electrocardiogram abnormalities (inc QT prolongation)*, International normalised ratio abnormal*, Gastric pH decreased, Platelet aggregation increased, Troponin I increased, Virus identification and serology*, Urine analysis abnormal*
Hætteglasset ligger i en transparent blisterpakning bestående af en bakke med et låg. 
The vial is contained in a transparent blister pack consisting of a tray with a lid. Each pack contains 1 single-use vial.
Hos patienter med fremskreden myelom var sværhedsgraden af trombocytopeni relateret til trombocyttallet før behandlingen: For trombocyttal ved baseline < 75 x 109/l havde 90 % af 21 patienter et tal på ≤ 25 x 109/l under studiet, herunder 14 % < 10 x 109/l. 
In patients with advanced myeloma the severity of thrombocytopenia was related to pre-treatment platelet count: for baseline platelet counts < 75,000/μl, 90% of 21 patients had a count ≤ 25,000/μl during the study, including 14% < 10,000/μl; in contrast, with a baseline platelet count > 75,000/μl, only 14% of 309 patients had a count ≤ 25,000/μl during the study.
România Terapia S.A. 
Terapia S.A.
Bilirubin 
Bilirubin level
Pegyleret liposomal doxorubicin administreres i en dosis på 30 mg/m2 på dag 4 af Bortezomib SUNbehandlingscyklussen som en 1-times intravenøs infusion, der administreres efter Bortezomib SUNinjektionen. 
Pegylated liposomal doxorubicin is administered at 30 mg/m2 on day 4 of the Bortezomib SUN treatment cycle as a 1 hour intravenous infusion administered after the Bortezomib SUN injection.
synstab eller -forstyrrelser og kortåndethed - Hukommelsestab, nedsat tankevirksomhed, gangbesvær eller synstab. 
visual loss or disturbances and shortness of breath - memory loss, trouble thinking, difficulty with walking or loss of vision.
Du vil få 4 behandlingscyklusser (12 ugers behandling). 
You will receive 4 cycles (12 weeks).
• at kravene til rekonstitution er forskellige ved intravenøs (i.v.) 
• different reconstitution requirements for intravenous (IV) or subcutaneous (SC) use
- Injicer opløsningen subkutant i en vinkel på 45-90°. 
- Inject the solution subcutaneously, under a 45-90°angle.
Almindelig Muskelspasmer*, muskuloskeletale smerter*, ekstremitetssmerter 
Common Muscle spasms*, Musculoskeletal pain*, Pain in extremity
REKONSTITUTION TIL INTRAVENØS INJEKTION 
RECONSTITUTION FOR INTRAVENOUS INJECTION
HBV-infektion med dødelig udgang forekom hos 0,8 % (n=2) af patienterne i non-bortezomib-armen (rituximab, cyclophosphamid, doxorubicin, vincristin og prednison; R-CHOP) og hos 0,4 % (n=1) af patienterne i armen med bortezomib plus rituximab, cyclophosphamid, doxorubicin og prednison (BzmbR-CAP). 
HBV infection with fatal outcomes occurred in 0.8% (n=2) of patients in the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP ) and 0.4% (n=1) of patients receiving bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BzmbR-CAP).
bakteriel), Epstein-Barr-virusinfektion, herpes genitalis, tonsillitis, mastoiditis, postviralt træthedssyndrom 
Meningitis (inc bacterial), Epstein-Barr virus infection, Genital herpes, Tonsillitis, Mastoiditis, Post viral fatigue syndrome
Klinisk virkning ved recidiverende eller refraktær myelomatose Sikkerheden og effekten ved bortezomib (som intravenøs injektion) blev vurderet i to studier med den anbefalede dosis på 1,3 mg/m2: et randomiseret, komparativt fase III-studie (APEX) versus dexamethason (Dex) med 669 patienter med recidiverende eller refraktær myelomatose, som havde fået 1-3 tidligere behandlinger, og et fase II-studie med en enkelt gruppe med 202 patienter med recidiverende eller refraktær myelomatose, som havde fået mindst 2 tidligere behandlinger, og som i deres seneste behandlingsregime havde oplevet progression. 
Clinical efficacy in relapsed or refractory multiple myeloma The safety and efficacy of bortezomib (injected intravenously) were evaluated in 2 studies at the recommended dose of 1.3 mg/m2: a Phase III randomised, comparative study (APEX), versus dexamethasone (Dex), of 669 patients with relapsed or refractory multiple myeloma who had received 1-3 prior lines of therapy, and a Phase II single-arm study of 202 patients with relapsed and refractory multiple myeloma, who had received at least 2 prior lines of treatment and who were progressing on their most recent treatment.
Bortezomibs sikkerhedsprofil vurderet hos 240 MCL-patienter behandlet med bortezomib i en dosis på 1,3 mg/m2 i kombination med rituximab, cyclophosphamid, doxorubicin og prednison (BzmbRCAP) kontra 242 patienter behandlet med rituximab, cyclophosphamid, doxorubicin, vincristin og prednison [R-CHOP] var relativt overensstemmende med den, som blev observeret hos patienter med myelomatose, med de væsentligste forskelle beskrevet nedenfor. 
Mantle cell lymphoma (MCL) The safety profile of bortezomib in 240 MCL patients treated with bortezomib at 1.3 mg/m2 in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BzmbR-CAP) versus 242 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] was relatively consistent to that observed in patients with multiple myeloma with main differences described below.
20,7 mdr. 
20.7 mo
18,3 mdr. 
18.3 mo
Perifer neuropati ved kombinationsbehandlinger 
Peripheral neuropathy in combination regimens Multiple myeloma
og seponeringsraten på grund af perifer neuropati var 8 % lavere i den subkutane gruppe i forhold til den intravenøse gruppe. 
In addition, the incidence of Grade 3 or higher peripheral neuropathies was 10% lower, and the discontinuation rate due to peripheral neuropathies 8% lower for the subcutaneous group as compared to the intravenous group.
- I tilfælde af lokale reaktioner på injektionsstedet efter en subkutan injektion af Bortezomib SUN anbefales det enten at administrere en mindre koncentreret opløsning af Bortezomib SUN (1 mg/ml i stedet for 2,5 mg/ml) subkutant eller skifte til intravenøs administration. 
- If local injection site reactions occur following Bortezomib SUN injection subcutaneously, either a less concentrated Bortezomib SUN solution (1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.
sammen med lægemidlerne melphalan og prednison til behandling af patienter, der ikke tidligere er blevet behandlet for sygdommen, og som ikke er egnede til højdosiskemoterapi med transplantation af blodstamceller. 
in combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation.
Pyreksi*, træthed, asteni 
Pyrexia*, Fatigue, Asthenia
Samtidig behandling med andre lægemidler Patienterne skal monitoreres omhyggeligt, når der gives bortezomib sammen med kraftige CYP3A4hæmmere. 
Patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors.
Bortezomib SUN indeholder: - Aktivt stof: bortezomib. 
What Bortezomib SUN contains - The active substance is bortezomib.
Når Bortezomib SUN gives i kombination med andre lægemidler, henvises der til produktresuméerne for disse lægemidler vedrørende anvisninger i administration. 
When Bortezomib SUN is given in combination with other medicinal products, refer to the Summary of Product Characteristics of these products for instructions for administration.
Bortezomib SUN vil blive givet af sundhedspersonale, som har erfaring med behandling med cytostatika. 
Bortezomib SUN will be administered by a health care professional experienced in the use of cytotoxic medicines.
CI=konfidensinterval; CR=komplet respons; nCR=næsten komplet respons; ITT=intent to treat; RR=responsrate; Bzmb=bortezomib; BzmbDx=bortezomib, dexamethason; VDDx=vincristin, doxorubicin, dexamethason; VGPR=virkeligt godt partielt respons; PR=partielt respons; OR=oddsratio. 
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Bzmb=bortezomib; BzmbDx=bortezomib, dexamethasone; VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response; PR=partial response; OR=odds ratio.
Denne 4-ugers periode kaldes en behandlingscyklus. 
This 4-week period is considered a treatment cycle.
Bortezomib metaboliseres af leverenzymer. 
Bortezomib is metabolised by liver enzymes.
Du må ikke amme, mens du behandles med Bortezomib SUN. 
You should not breast-feed while using Bortezomib SUN.
Bortezomib SUN-behandling skal indstilles i op til 2 uger, indtil patienten har ANC ≥ 0,75 x 109 celler/l og trombocyttal ≥ 25 x 109 celler/l. 
Bortezomib SUN therapy should be withheld for up to 2 weeks until the patient has an ANC ≥ 750 cells/μl and a platelet count ≥ 25,000 cells/μl.
- Hvis trombocyttallet er < 25 x 109 celler/l, eller ANC er < 0,75 x 109 celler/l på en dag med Bortezomib SUN-dosering (undtagen dag 1 i hver cyklus) 
- If platelet counts ≤ 30 x 109/l or ANC ≤ 0.75 x 109/l on a Bortezomib SUN dosing day (other than day 1)